Table 1.
Baseline Characteristics Among Propensity-Matched Cohort by Albuminemia
| Characteristic | Hypoalbuminemia (n = 130) |
Normoalbuminemia (n = 130) |
P Value |
|---|---|---|---|
| Age, y | 65.2 (56.0–80.6) | 70.3 (56.4–82.5) | .34 |
| Female sex, No. (%) | 78 (60.0) | 77 (59.2) | .90 |
| BMI, kg/m2 | 25.9 (21.9–31.3) | 28.0 (24.0–33.7) | .09 |
| Average CRO dose, g/d | 1.6 (1.0–1.9) | 1.6 (1.0–1.8) | .60 |
| Duration of CRO, d | 4.9 (3.9–7.0) | 5.1 (3.9–7.4) | .51 |
| Time to first effective antibiotica, h | 1.6 (0.7–2.9) | 1.1 (0.3–2.6) | .06 |
| Time to CRO initiationb, h | 5.2 (1.4–32.6) | 2.1 (0.5–8.6) | <.01 |
| Infection source, No. (%) | |||
| Intravenous catheter | 5 (3.8) | 1 (0.8) | .10 |
| Intra-abdominal | 19 (14.6) | 13 (10.0) | .26 |
| LVAD driveline | 0 (0.0) | 1 (0.8) | 1.00 |
| Skin and soft tissue | 1 (0.8) | 1 (0.8) | 1.00 |
| Urinary tract | 87 (66.9) | 99 (76.1) | .10 |
| Unknown | 18 (13.8) | 15 (11.5) | .58 |
| Plasma albumin, g/dL | 2.2 (2.0–2.4) | 3.2 (2.8–3.5) | <.01 |
| Serum creatinine, g/dL | 1.6 (1.2–2.2) | 1.6 (1.1–2.4) | .58 |
| WBC count, cells × 103/µL | 15.0 (10.9–20.5) | 15.4 (10.7–19.2) | .54 |
| Temperature, °C | 38.2 (37.4–39.1) | 38.1 (37.6–38.9) | .82 |
| ICU admission, No. (%) | 41 (31.5) | 41 (31.5) | 1.00 |
| Mechanical ventilation, No. (%) | 8 (6.2) | 8 (6.2) | 1.00 |
| Vasopressor use, No. (%) | 9 (6.9) | 7 (5.4) | .61 |
| SOFA scorec | 4 (2.0–6.0) | 4 (2.0–6.0) | .57 |
| Pitt bacteremia scored | 2 (1.0–3.0) | 2 (1.0–3.0) | .99 |
| Comorbidities, No. (%) | |||
| Immunosuppression | 18 (13.8) | 18 (13.8) | 1.00 |
| Cirrhosis | 14 (10.8) | 7 (5.4) | .11 |
| Malignancy | 17 (13.1) | 13 (10.0) | .44 |
| COPD | 10 (7.7) | 14 (10.8) | .39 |
| Diabetes mellitus | 55 (42.3) | 58 (44.6) | .71 |
| Chronic kidney disease | 104 (80.0) | 102 (78.5) | .76 |
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRO, ceftriaxone; ICU, intensive care unit; LVAD, left ventricular assist device; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell.
Time from culture collection, excluding patients on effective therapy at the time of culture collection (n = 123 and n = 125, respectively).
Time from culture collection, excluding patients on CRO at the time of culture collection (n = 128 and n = 127, respectively).
Number of patients with missing data: partial pressure of oxygen in arterial blood, n = 232; bilirubin, n = 1.
No patients with missing data.